| Schedule of Segment Reporting Information, by Segment [Table Text Block] |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | Net sales: | | | | | | | | | | | | | | | | | | Biotechnology | | $ | 110,029 | | | $ | 94,516 | | | $ | 306,516 | | | $ | 267,256 | | | Protein Platforms | | | 25,539 | | | | 23,586 | | | | 79,566 | | | | 64,707 | | | Diagnostics | | | 28,548 | | | | 25,978 | | | | 76,963 | | | | 74,542 | | | Intersegment | | | (143 | ) | | | (43 | ) | | | (306 | ) | | | (80 | ) | | Consolidated net sales | | $ | 163,973 | | | $ | 144,037 | | | $ | 462,739 | | | $ | 406,425 | | | Operating income: | | | | | | | | | | | | | | | | | | Biotechnology | | $ | 53,013 | | | $ | 45,242 | | | $ | 143,826 | | | $ | 127,195 | | | Protein Platforms | | | 2,461 | | | | 3,256 | | | | 11,636 | | | | 5,308 | | | Diagnostics | | | 7,988 | | | | 6,004 | | | | 17,594 | | | | 18,108 | | | Segment operating income | | $ | 63,462 | | | $ | 54,502 | | | $ | 173,056 | | | $ | 150,611 | | | Costs recognized on sale of acquired inventory | | | (1,431 | ) | | | (637 | ) | | | (2,013 | ) | | | (2,770 | ) | | Amortization of acquisition related intangible assets | | | (11,872 | ) | | | (11,689 | ) | | | (34,547 | ) | | | (33,504 | ) | | Acquisition related expenses | | | (1,312 | ) | | | (3,993 | ) | | | (23,994 | ) | | | (19,581 | ) | | Stock based compensation | | | (4,748 | ) | | | (3,974 | ) | | | (13,587 | ) | | | (11,219 | ) | | Corporate general, selling, and administrative expenses | | | (1,015 | ) | | | (707 | ) | | | (5,652 | ) | | | (2,999 | ) | | Consolidated operating income | | $ | 43,084 | | | $ | 33,502 | | | $ | 93,263 | | | $ | 80,538 | | |